LQDA Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -520.57% compared to Liquidia's net margin of --. Liquidia's return on equity of -168.37% beat Armata Pharmaceuticals's return on equity of --.

Liquidia has a consensus price target of $25.30, signalling upside risk potential of 127.93%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 258.97%. Given that Armata Pharmaceuticals has higher upside potential than Liquidia, analysts believe Armata Pharmaceuticals is more attractive than Liquidia.

Liquidia has a beta of 0.220, which suggesting that the stock is 78.016% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.777, suggesting its less volatile than the S&P 500 by 22.301%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Liquidia's net income of -$23.2M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, Liquidia's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 52.59x versus 706.46x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -520.57% compared to Liquidia's net margin of --. Liquidia's return on equity of -168.37% beat Perspective Therapeutics's return on equity of --.

Liquidia has a consensus price target of $25.30, signalling upside risk potential of 127.93%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Liquidia, analysts believe Perspective Therapeutics is more attractive than Liquidia.

Liquidia has a beta of 0.220, which suggesting that the stock is 78.016% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Liquidia's net income of -$23.2M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Liquidia's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 52.59x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -520.57% compared to Liquidia's net margin of 18.02%. Liquidia's return on equity of -168.37% beat Protalix BioTherapeutics's return on equity of -29.54%.

Liquidia has a consensus price target of $25.30, signalling upside risk potential of 127.93%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 695.46%. Given that Protalix BioTherapeutics has higher upside potential than Liquidia, analysts believe Protalix BioTherapeutics is more attractive than Liquidia.

Liquidia has a beta of 0.220, which suggesting that the stock is 78.016% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Liquidia's net income of -$23.2M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Liquidia's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 52.59x versus 3.03x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -520.57% compared to Liquidia's net margin of 41.27%. Liquidia's return on equity of -168.37% beat United Therapeutics's return on equity of 19.26%.

Liquidia has a consensus price target of $25.30, signalling upside risk potential of 127.93%. On the other hand United Therapeutics has an analysts' consensus of $335.33 which suggests that it could grow by 9.5%. Given that Liquidia has higher upside potential than United Therapeutics, analysts believe Liquidia is more attractive than United Therapeutics.

Liquidia has a beta of 0.220, which suggesting that the stock is 78.016% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.563%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are smaller than United Therapeutics quarterly revenues of $748.9M. Liquidia's net income of -$23.2M is lower than United Therapeutics's net income of $309.1M. Notably, Liquidia's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 15.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 52.59x versus 6.38x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.